Overview

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.
Phase:
Phase 2
Details
Lead Sponsor:
Angiochem Inc
Treatments:
Paclitaxel